Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Dermatologic 1

Conditions

Precancerous Conditions 1Keratosis, Actinic 1Carcinoma, Squamous Cell 1

Interventions

Cyclophosphamide 7fludarabine phosphate 6Peripheral Blood Stem Cell Transplantation 6Whole-Body Irradiation 5Tacrolimus 4Mycophenolic Acid 4Melphalan 4Busulfan 4Sulindac 3Methotrexate 3Biopsy 3Antilymphocyte Serum 3fludarabine 2Sirolimus 2Patient Reported Outcome Measures 2Mesna 2Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 2Gene Expression Profiling 2Etoposide 2Epoetin Alfa 2Eflornithine 2Cyclosporine 2Cetuximab 2Celecoxib 2vandetanib 1tanespimycin 1sintilimab 1perillyl alcohol 1antitumor A 1aldesleukin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Precancerous Conditions × Excipients × Clear all
NCT02844777 2023-01-12

Efficacy and Safety of VDA-1102 Ointment in the Treatment of Actinic Keratosis

Vidac Pharma

Phase 2 Completed
93 enrolled 13 charts
DermatologicOther neoplasm

Carcinoma, Squamous Cell, Precancerous Conditions, Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡